ClinicalTrials.gg
Active, not recruitingNCT06120491EvoPAR-PR01Updated Nov 10, 2026

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

A Phase 3 interventional study of Saruparib and Placebo in Metastatic Castration-Sensitive Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 322 sites in 24 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,898
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Enrollment
4th of 60
1,898 · median 110
Started
2023
with 2 others
Phase 3
17 of 91
3 open now
Primary completion
2027-09
later than 13 of 28 live
Registered
71st of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 4th largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2023, is one of 17 in phase 3, reaches primary completion later than 13 of the 28 other live ones, and was the 71st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Read the detailed description

Approximately 1800 adult participants with mCSPC will be assigned to one of two cohorts (550 HRRm and 1250 non-HRRm) and randomized in a 1:1 ratio to receive either Saruparib (AZD5305) with NHA or placebo with NHA. They will receive their assigned treatment and regular tumor evaluation scans until disease progression, or until treatment is stopped for another reason.

All patients will be followed for survival until the end of the study. Independent data monitoring committee (DMC) composed of independent experts will be convened to confirm the safety and tolerability of Saruparib (AZD5305) + physicians choice NHA.

03

Conditions studied

  • Metastatic Castration-Sensitive Prostate Cancer

Browse trials for

Keywords

  • AZD5305; Saruparib; HRRm; non-HRRm; mCSPC; Prostate Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male ≥ 18 years of age.
  • documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible.
  • disease as documented by the investigator prior to randomisation, with clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI.
  • Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting ≥ 14 days and \< 4 months prior to randomisation.
  • performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation.
  • Provision of FFPE tumour tissue sample and blood sample (for ctDNA).
  • Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility.
  • Adequate organ and bone marrow function as described in study protocol.
  • Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention.
  • Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no clinical MDS/AML suspicion, no specific screening for MDS/AML (by BM/bone ) is required.
  • Participants with any known predisposition to bleeding.
  • Any history of persisting (> 2 weeks) severe cytopenia.
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA.
  • History of another primary , with exceptions.
  • Persistent toxicities ( Grade ≥ 2) caused by previous anticancer therapy.
  • Spinal cord compression or unless asymptomatic, stable, and not requiring for at least 4 weeks prior to start of study intervention.
  • Cardiac criteria, including history of arrhythmia and cardiovascular disease.
  • Any prior anticancer pharmacotherapy or surgery for prostate cancer, with exceptions.
  • Prior treatment within 14 days with blood product support or growth factor support.
  • Participants who are unevaluable for both bone and soft tissue progression.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,898 participants (actual)

Study arms

  • Experimental
    Arm 1: Saruparib (AZD5305) + Physician's Choice NHA

    Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)

    Drug: Saruparib · Drug: Abiraterone Acetate · Drug: Darolutamide · Drug: Enzalutamide

  • Placebo comparator
    Arm 2: Placebo + Physician's Choice NHA

    Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)

    Drug: Placebo · Drug: Abiraterone Acetate · Drug: Darolutamide · Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or, death due to any cause.

    Time frame: Up to approximately 50 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 90 months

  2. Second Progression-Free Survival (PFS2)

    Time from randomisation to PFS2 is defined as the time from randomisation to the earliest of progression (defined as radiographic progression, clinical progression, or PSA progression) after initiation of first subsequent treatment following the initial investigator-assessed progression or death.

    Time frame: Up to approximately 50 months

  3. Time to First Subsequent Therapy or Death (TFST)

    TFST is defined as the time from randomisation to the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause.

    Time frame: Up to approximately 50 months

  4. Symptomatic Skeletal Event-Free Survival (SSE-FS)

    SSE-FS is defined as the time from randomisation to the earliest of the following: * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). * Occurrence of spinal cord compression. * Orthopaedic surgical intervention for bone metastasis. * Death due to any cause.

    Time frame: Up to approximately 50 months

  5. Time to the First Castration-Resistant Event (TTCR)

    TTCR is defined as the time from randomisation to the first castration resistant event (radiographic disease progression per RECIST 1.1 \[soft tissue\] and/or PCWG3 criteria \[bone\], PSA progression per PCWG3, or SSE, PSA progression per PCWG3, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL).

    Time frame: Up to approximately 50 months

  6. Time to Pain Progression (TTPP)

    TTPP is defined as the time from randomisation to clinically meaningful pain progression based on a 2-point increase from baseline in the Brief Pain Inventory - Short Form (BPI-SF) Item 3 'worst pain in 24 hours' score and/or initiation of/increase in opioid analgesic use.

    Time frame: Up to approximately 50 months

  7. Time To Deterioration in Urinary Symptoms (TTDUS)

    TTDUS is defined as the time from randomisation to deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Prostate Questionnaire (Urinary Symptoms) (QLQPR25 \[US\]) subscale scores.

    Time frame: Up to approximately 50 months

  8. Time to Deterioration in Physical Function (TTDPF)

    TTDPF is defined as the time from randomisation to deterioration in PROMIS Physical Function Short Form 8C scores, or death due to any cause.

    Time frame: Up to approximately 50 months

  9. Health-related Quality of Life (HrQoL)

    Change from baseline in BPI-SF worst pain score, pain severity, and interference domain scores.

    Time frame: Up to approximately 50 months

  10. BRCA, other HRR gene mutation and HRD status

    Time frame: At screening

  11. Plasma concentrations of AZD5305

    Time frame: Up to approximately 10 months

  12. Samples will be used to develop complementary or companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study.

    Samples will be tested by a CDx to certify consistency with assays used in the study.

    Time frame: Up to approximately 50 months

  13. Assessment of PSA (prostate-specific antigen) in participants in mCSPC

    proportion of participants achieving a \>= 50% or \>=90% decrease in PSA from baseline; proportion of participants with undetectable PSA (\< 0.2 ng/mL); time to PSA progression

    Time frame: Up to approximately 50 months

Other outcomes

  1. Number of TEAEs (treatment emergent adverse events), SAEs (serious adverse events), and AEs (adverse events) leading to dose modifications

    Time frame: Up to approximately 50 months

07

Study locations

322 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Los Angeles, California 90073, United States
  • Research Site
    Montebello, California 90640, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Golden, Colorado 80401, United States
  • Research Site
    Lakewood, Colorado 80228, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Glenview, Illinois 60026, United States
  • Research Site
    Lake Barrington, Illinois 60010, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Scarborough, Maine 04074, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Upper Marlboro, Maryland 20774, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Troy, Michigan 48084, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Bozeman, Montana 59715, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cincinnati, Ohio 45212, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cleveland, Ohio 44111, United States
  • Research Site
    Cleveland, Ohio 44124, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Portland, Oregon 97227, United States
  • Research Site
    Bala-Cynwyd, Pennsylvania 19004-1017, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77025, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Sugar Land, Texas 77479, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Wichita Falls, Texas 76310, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    St. George, Utah 84790, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Spokane, Washington 99202, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Chermside, 4032, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Hyde Park, 4812, Australia
  • Research Site
    Kurralta Park, 5037, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Krems, 3500, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Vienna, 1020, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Curitiba, 80810-050, Brazil
  • Research Site
    Pelotas, 96020-080, Brazil
  • Research Site
    Porto Alegre, 90035-001, Brazil
  • Research Site
    Rio de Janeiro, 22775-001, Brazil
  • Research Site
    Salvador, 41950-640, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01323-903, Brazil
  • Research Site
    São Paulo, 05652000, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Calgary, Alberta T2V 1P9, Canada
  • Research Site
    Abbotsford British Columbia, British Columbia V2S 2J4, Canada
  • Research Site
    Abbotsford British Columbia, British Columbia V2T 1X8, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1H7, Canada

Showing the first 100 of 322 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Azad AA, Agarwal N, Armstrong AJ, Hellmis E, Sugimoto M, Urun Y, Xing N, Aregay M, Lima J, Meulendijks D, Chi KN. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Future Oncol. 2026 Apr;22(10):1153-1163. doi: 10.1080/14796694.2026.2655433. Epub 2026 Apr 14. PubMed 41979035 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2027, 46 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 46 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Nov 7, 2023
StartActual
Nov 21, 2023
Primary completionEst.
Sep 30, 2027
CompletionEst.
Apr 30, 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06120491
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Nov 21, 2023
Primary completion
Sep 30, 2027 (estimated)
Completion
Apr 30, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Kim Nguyen Chi, MD
principal investigator · BC Cancer, Canada
Arun Azad, MD
principal investigator · Peter MacCallum Cancer Centre, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5305

Start the discussion